company background image
0QAI logo

Adocia LSE:0QAI Stock Report

Last Price

€8.76

Market Cap

€123.3m

7D

-9.2%

1Y

212.8%

Updated

28 Mar, 2024

Data

Company Financials +

0QAI Stock Overview

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases.

0QAI fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Adocia SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Adocia
Historical stock prices
Current Share Price€8.76
52 Week High€16.16
52 Week Low€2.80
Beta0.90
1 Month Change-9.98%
3 Month Change-28.55%
1 Year Change212.84%
3 Year Change-17.02%
5 Year Change-37.22%
Change since IPO-87.44%

Recent News & Updates

Recent updates

Shareholder Returns

0QAIGB BiotechsGB Market
7D-9.2%0.2%2.3%
1Y212.8%-27.3%2.7%

Return vs Industry: 0QAI exceeded the UK Biotechs industry which returned -27.5% over the past year.

Return vs Market: 0QAI exceeded the UK Market which returned 3.7% over the past year.

Price Volatility

Is 0QAI's price volatile compared to industry and market?
0QAI volatility
0QAI Average Weekly Movement8.9%
Biotechs Industry Average Movement7.9%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.5%

Stable Share Price: 0QAI's share price has been volatile over the past 3 months.

Volatility Over Time: 0QAI's weekly volatility has decreased from 14% to 9% over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
200597Olivier Soulahttps://www.adocia.com

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company’s clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide.

Adocia SA Fundamentals Summary

How do Adocia's earnings and revenue compare to its market cap?
0QAI fundamental statistics
Market cap€123.34m
Earnings (TTM)-€20.54m
Revenue (TTM)€10.84m

11.4x

P/S Ratio

-6.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QAI income statement (TTM)
Revenue€10.84m
Cost of Revenue€25.30m
Gross Profit-€14.46m
Other Expenses€6.09m
Earnings-€20.54m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Apr 24, 2024

Earnings per share (EPS)-1.46
Gross Margin-133.32%
Net Profit Margin-189.46%
Debt/Equity Ratio-119.7%

How did 0QAI perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.